Skip to content
Trial Agents

Tempus Labs

Tempus Labs is recorded as a service provider in 33 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.

33distinct trials
15recorded service labels
2trials with learnings

Data snapshot: 2026-10-09 · About the data

Clinical trial experience

Showing 20 of 33 trials · Latest update first

A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1-Positive Squamous Cell Carcinoma of the Head and Neck

Sponsor Glaxosmithkline Research & Development Limited

Start (EU)
Latest update
Estimated end

A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer

Sponsor Xencor Inc.

Start (EU)
Latest update
Estimated end
Operational learnings available3 trial-level findings · Read insights
  • Twenty-two clinical sites enrolled subjects across Belgium, Greece, Malaysia, the Netherlands, Portugal, Spain, Taiwan, and the United States.
  • After review of data from the first two subjects enrolled at 750 mg, the IMC modified Part 1 randomization so that subsequently enrolled subjects received either 500 mg or 750 mg.
  • After reviewing 28 randomized and treated Part 1 subjects, the IMC recommended ending enrollment and not initiating Part 2.

These findings describe the trial, not the service provider’s performance or responsibility.

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP 5336) in Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation

Sponsor Sumitomo Pharma America Inc.

Start (EU)
Latest update
Estimated end

A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients with Selected Advanced Solid Tumors

Sponsor ADC Therapeutics S.A.

Start (EU)
Latest update
Estimated end
Operational learnings available4 trial-level findings · Read insights
  • Enrollment was substantially below plan: 30 patients were enrolled globally versus approximately 132 planned.
  • Part 1 enrolled 26 of 92 planned patients and Part 2 enrolled 4 of 40 planned patients; backfilling was not opened.
  • The study operated at 13 sites: 4 in Spain, 2 in the United Kingdom, and 7 in the United States.
  • Following the single response observed in cholangiocarcinoma during Part 1, Part 2 enrolled only patients with cholangiocarcinoma; no response was observed in Part 2.

These findings describe the trial, not the service provider’s performance or responsibility.

A Phase 2, multicenter, randomized, open-label trial of GEN1046 as monotherapy and in combination with Pembrolizumab in subjects with relapsed/refractory metastatic non-small cell lung cancer after treatment with standard care therapy with a immune checkpoint inhibitor.

Sponsor Genmab A/S

Start (EU)
Latest update
Estimated end

A Phase 1/Phase 2, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis

Sponsor Sumitomo Pharma America Inc.

Start (EU)
Latest update
Estimated end

A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non small Cell Lung Cancers, Negative for PD L1, and Positive for KRAS p.G12C (CodeBreaK 202)

Sponsor Amgen Inc.

Start (EU)
Latest update
Estimated end

An open-label, multicenter, randomized Phase 2 study of the ATR inhibitor tuvusertib in combination with the PARP inhibitor niraparib or the ATM inhibitor lartesertib in participants with BRCA mutant and/or homologous recombination deficiency (HRD) positive epithelial ovarian cancer that progressed on prior PARP inhibitor therapy (DDRiver EOC 302)

Sponsor Merck Healthcare KGaA

Start (EU)
Latest update
Estimated end

Questions about this trial experience

What services are recorded for Tempus Labs?

The 2026-10-09 snapshot links Tempus Labs to 33 distinct CTIS trials. Recorded services include Laboratory services, Plasma cfDNA sample analysis, Biomarker Analysis for Blood & Tissue, Biomarker analysis- Tumor RNA/DNA Analysis, among 15 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.

Which therapeutic areas and study phases are recorded for Tempus Labs?

The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gynecology, Haematological Malignancies, Respiratory. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.

In which countries are trials linked to Tempus Labs conducted?

The linked trials record locations in 21 countries, including Spain, Italy, France, Germany, Netherlands. These are trial locations, not confirmed office locations or countries where Tempus Labs delivered services.

What can this page tell me about Tempus Labs's trial experience?

Browse 33 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.

About this data & company names

One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.

Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.

Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Tempus Labs. Legacy brands remain separate unless explicitly matched in the name registry.

View recorded company names
  • Tempus Labs Inc.

Never miss a new clinical trial insight

We continuously analyze new and updated clinical trial data and publish practical, evidence-led reports for clinical leaders.

By entering your email, you agree to receive emails from Trial Agents. You can unsubscribe anytime.